Extracellular matrix (ECM) components, such as heparan sulfate (HS) proteoglycans, and their enzymatic remodeling may also affect insulin-INSR signaling axis [12–15], however direct contribution of these factors to accelerated breast tumor progression/aggressiveness in patients with metabolic disorders remained underappreciated. Here, INS is linked to metabolic disease.